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Growing Impact of Restenosis on the Surgical Treatment of Peripheral
Arterial Disease
Douglas W. Jones, MD; Andres Schanzer, MD; Yuanyuan Zhao, MA; Todd A. MacKenzie, PhD; Brian W. Nolan, MD; Michael S. Conte, MD;
Philip P. Goodney, MD, MS; for the Vascular Study Group of New England
Background-—Patients with peripheral arterial disease often experience treatment failure from restenosis at the site of a prior
peripheral endovascular intervention (PVI) or lower extremity bypass (LEB). The impact of these treatment failures on the utilization
and outcomes of secondary interventions is poorly understood.
Methods and Results-—In our regional vascular quality improvement collaborative, we compared 2350 patients undergoing
primary infrainguinal LEB with 1154 patients undergoing secondary infrainguinal LEB (LEB performed after previous
revascularization in the index limb) between 2003 and 2011. The proportion of patients undergoing secondary LEB increased
by 72% during the study period (22% of all LEBs in 2003 to 38% in 2011, P<0.001). In-hospital outcomes, such as myocardial
infarction, death, and amputation, were similar between primary and secondary LEB groups. However, in both crude and
propensity-weighted analyses, secondary LEB was associated with signiﬁcantly inferior 1-year outcomes, including major adverse
limb event-free survival (composite of death, new bypass graft, surgical bypass graft revision, thrombectomy/thrombolysis, or
above-ankle amputation; Secondary LEB MALE-free survival = 61.6% vs primary LEB MALE-free survival = 67.5%, P=0.002) and
reintervention or amputation-free survival (composite of death, reintervention, or above-ankle amputation; Secondary LEB RAO-free
survival = 58.9% vs Primary LEB RAO-free survival 64.1%, P=0.003). Inferior outcomes for secondary LEB were observed
regardless of the prior failed treatment type (PVI or LEB).
Conclusions-—In an era of increasing utilization of PVI, a growing proportion of patients undergo LEB in the setting of a prior failed
PVI or surgical bypass. When caring for patients with peripheral arterial disease, physicians should recognize that ﬁrst treatment
failure (PVI or LEB) affects the success of subsequent revascularizations. ( J Am Heart Assoc. 2013;2:e000345 doi: 10.1161/
JAHA.113.000345)
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T he treatment of peripheral arterial disease (PAD) haschanged dramatically in recent years, as the use of
peripheral endovascular interventions (PVIs) has increased
and the use of lower extremity bypass (LEB) surgery has
decreased.1–3 In fact, the increase in PVIs has outpaced the
decline in LEB by a factor of >3:1,4 suggesting either a shift in
treatment threshold, a rising rate of repeat treatments for a
single patient, or some combination thereof. As a result, the
total number of procedures being performed for PAD has
increased, a trend associated withmarkedly increased costs.1,4
When considering potential reasons for the increasing cost
and complexity of caring for patients with PAD, many have
expressed concern about a rising incidence of restenosis.4–6
Repeat procedures, necessitated by initial treatment failure,
may be responsible for the rising number of revascularizations
being performed for PAD. Why might more secondary
revascularizations be occurring in recent years? It is well
known that physicians and patients commonly consider
tradeoffs between the relative durability and the relative
morbidity of competing treatments. For example, while the
short-term failure rate for tibial angioplasty is high, it is much
less invasive than that of surgical bypass and therefore has
been adopted by many specialists as an initial strategy.7 Part
of this rationale is also predicated on the notion that failure of
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endovascular interventions can still be salvaged by either
repeat PVI or bypass surgery, the validity of which has
increasingly come into question.8–10 It remains unclear how
these shifting practice patterns have inﬂuenced the patient
population undergoing LEB in recent years and whether
“downstream effects” of prior failed interventions have an
impact on the outcomes of bypass surgery.
The primary objectives of this study were to gain a better
understanding of whether the characteristics of patients
requiring surgical bypass for PAD have changed as practice
patterns have evolved and to address whether prior treat-
ments have downstream effects on the outcomes of surgical
bypass. To address these goals, we analyzed all patients
undergoing LEB in the Vascular Study Group of New England
(VSGNE), a large regional dataset of patients with vascular
disease. We used crude and inverse propensity-weighted
analyses to compare the incidence and outcomes of primary
LEB with those of LEB performed in the setting of a prior
ipsilateral PVI or bypass (secondary LEB).
Methods
Database and Cohort Assembly
Patients undergoing LEB at 1 of the 26 community and
academic centers in the Vascular Study Group of New
England (VSGNE) between 2003 and 2011 were included in
our study. While 6 centers participated in the VSGNE in 2003,
20 additional centers were added during the study period.
Data from all 26 centers are presented here, but our overall
ﬁndings were similar in size and effect when the analysis was
limited to data from only the original 6 centers. Details
regarding the VSGNE have previously been published11 and
are available online at http://www.vsgne.com. In this dataset,
>70 preoperative, intraoperative, and postoperative variables
are collected, as well as 1-year follow-up outcomes.5,8 A
claims-based audit system is used and has demonstrated 99%
accuracy in capturing consecutive procedures performed at
each center.5
Our main exposure variable was the occurrence of a
secondary bypass at the time of entry into the dataset.
A secondary bypass was deﬁned as a bypass performed in a
patient with a history of a prior ipsilateral PVI, a prior
ipsilateral LEB, or both. Primary LEB patients were those who
had no history of prior ipsilateral PVI or LEB recorded in the
database. Differences in patient characteristics were com-
pared across primary and secondary LEB patients using
existing data elements in the VSGNE, using the ﬁrst procedure
per patient as the unit of analysis. Patients were excluded
from this study if they had aneurysmal disease as the
indication for their procedure, if no indication was speciﬁed,
or if other variables were missing data. As a result, 12% of
patients undergoing LEB during the study period were
excluded, a majority of whom were missing an indication.
Among preoperative variables, indication for LEB was classi-
ﬁed as either intermittent claudication or critical limb
ischemia (CLI; deﬁned as tissue loss or ischemic rest pain).
Only the ﬁrst LEB procedure was considered for each patient
in the VSGNE dataset, and only infrainguinal LEB procedures
were included. This procedure was deﬁned as the index LEB. If
a patient had an LEB within the VSGNE and required a
subsequent ipsilateral LEB, these events were counted as
treatment failures (not as a new LEB).
Outcome Measures
Our primary outcome measures were chosen to target safety
and efﬁcacy of LEB using end points endorsed in the Society for
Vascular Surgery’s Objective Performance Goals.12 To evaluate
the safety and short-term efﬁcacy of LEB, we analyzed in-
hospital outcomes, including mortality, myocardial infarction,
and major amputation. We also examined outcomes at 1 year
postoperatively, including overall survival and amputation-free
survival. Additional efﬁcacy outcomes included reintervention
or amputation (RAO) and major adverse limb event (MALE),
deﬁned as follows: RAO-free survival is freedom from death,
any reintervention, or above-ankle amputation of index limb,
and MALE-free survival is freedom from death, major reinter-
vention (new bypass graft, a jump or interposition graft placed
during a revision, or thrombectomy/thrombolysis), or above
ankle-amputation of index limb.12 While summarizing out-
comes using RAO and MALE as endpoints allows insight into
the overall need for, and magnitude of, reinterventions, we also
individually report their component outcomes.
Statistical Analysis
Patient demographics were compared between groups using a
Wilcoxon rank sum test for continuous variables and v2 test
for categorical or dichotomous variables. The effects of
primary or secondary LEB on the time-to-event end points
(amputation-free survival, RAO-free survival, MALE-free sur-
vival, and overall survival) were estimated and contrasted
using Kaplan–Meier curves and log-rank tests for signiﬁcance
in conjunction with inverse propensity weighting. This
weighting approach corrects for imbalance due to measured
confounders by weighting subjects in each treatment group in
such a way that the weighted sample for each group
represents the entire sample of subjects. Weighted Kaplan–
Meier survival estimates were then calculated based on the
inverse of the probability that each patient would receive a
speciﬁc treatment (primary versus secondary LEB).13–16
Where inverse propensity-weighted survival estimates were
calculated, a Cox model was used to determine signiﬁcance of
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differences. Using this strategy, inverse propensity weighting
addresses issues of confounding, and because patients in our
database could not have been conceivably exposed to either
primary or secondary LEB, it serves as a sensitivity analysis
for consistency with our Cox models.
The propensity model for primary versus secondary LEB
was generated using a multivariable logistic regression model.
Backward stepwise logistic regression was used to determine
which preoperative patient characteristics and operative
details were most closely associated with secondary LEB at
the time of index bypass surgery. Following inverse propensity
weighting, patient characteristics were compared using
Wilcoxon rank-sum test or v2 test, where appropriate, to
examine the success of this technique in creating similar
cohorts for analysis. Outcomes were then analyzed in a
similar fashion as with the unweighted cohort. Data were
analyzed using STATA version 11 (StataCorp) and SAS version
9.2 (SAS Institute).
Results
Secular Changes in Secondary LEB
Between 2003 and 2011, the proportion of patients who
underwent secondary LEB within the VSGNE increased
signiﬁcantly, from 22% to 38% of all index LEBs performed
(P<0.001) (Figure 1). This increase was evident among
patients undergoing LEB for both claudication (23% to 33%,
P<0.001) and CLI (22% to 38%, P<0.001). When examining the
data by indication and nature of the prior intervention, the
greatest increases were seen in the frequency of prior PVI
(Figure 2). For example, we found that a history of prior PVI
increased from 13% to 22% for patients undergoing surgical
treatment for claudication (P=0.002), and similar increases
were evident for patients with CLI (12% to 25%, P<0.001). We
observed a smaller increase in the proportion of patients with
a history of LEB undergoing treatment for CLI (13% versus
19%; P=0.022) and no signiﬁcant change in the proportion of
patients with a history of LEB undergoing treatment for
claudication (P=0.323).
Patient Characteristics and Operative Details in
Primary Versus Secondary LEB
Between 2003 and 2011, a total of 3504 patients underwent an
index LEB procedure in the VSGNE database. Of these, 1154
(32.9%) were secondary LEBs, and 2350 (67.1%) were primary
LEBs. Secondary LEB followed prior ipsilateral PVI in 552 of
1154 cases (48%), prior ipsilateral LEB in 437 of 1154 cases
(38%), and both LEB and PVI in 165 of 1154 cases (14%).
Overall, the indication for LEB was claudication in 29.7%
(1039/3504) and CLI in 70.3% (2465/3504). These indications
Figure 1. Annual trends in secondary lower extremity bypass (LEB), as a proportion of total LEBs performed per year 2003–2011, stratiﬁed by
indication.
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were similar in primary and secondary LEB groups (Table 1).
However, patients undergoing a secondary LEB were more
likely to be younger (proportion under age 70: 58.5% versus
52.9%, P<0.001) and to have a higher rate of smoking (88.6%
versus 81.7%, P<0.001) and were less likely to be receiving
dialysis (5.6% versus 8.2%, P=0.004) than were primary LEB
patients. Patients undergoing a secondary LEB were also more
likely to be receiving aspirin (76.1% versus 72.2%, P=0.014),
clopidogrel (19.3% versus 8.3%, P<0.001), or a statin (70.8%
versus 63.3%, P<0.001) in the preoperative period. Additional
differences in patient characteristics are shown in Table 1.
Univariate analyses revealed differences in operative
characteristics between the 2 groups (Table 1). Secondary
LEB patients were more likely to have undergone the
procedure on an urgent or emergent basis (21.0% versus
18.6%, P=0.023), to have prosthetic conduit used for their
bypass graft (35.6% versus 27.3%, P<0.001) or to have a
spliced vein graft consisting of >1 piece of vein (7.5% versus
4.9%, P<0.001). Finally, secondary LEB patients were more
likely to be discharged on clopidogrel (25.9% versus 16.8%,
P<0.001), warfarin (27.7% versus 21.4%, P<0.001), and
statins (79.5% versus 74.0%, P=0.002) (Table 1).
Multivariable logistic regression analysis of patient demo-
graphics and operative details revealed multiple variables
associated with secondary LEB (Table 2). Using these differ-
ences, inverse propensity weighting was successful in creat-
ing 2 cohorts that were appropriate for comparison while
accounting for differences in demographics and operative
details (Table 3).
In-hospital Outcomes in Primary Versus
Secondary LEB, by Indication
Of the 3504 LEBs performed, unweighted postoperative in-
hospital outcomes showed no differences in mortality (1.6%
versus 1.5%, P=0.795) or myocardial infarction (4.1% versus
Figure 2. Annual trends in secondary LEB, as a proportion of total LEBs performed per year 2003–2011, stratiﬁed by indication and type of
intervention. CLI indicates critical limb ischemia; LEB, lower extremity bypass; PVI, peripheral endovascular intervention.
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Table 1. Complete Demographics and Operative Details of
Patients Who Underwent Infrainguinal LEB in the Vascular
Study Group of New England From 2003 to 2011, With
Univariate Analysis by Primary Versus Secondary LEB
Characteristic
Unweighted Data
Primary
LEB, %
Secondary
LEB, % P Value*
No. of patients 2350 1154
Demographics
Male sex 69.6 66.6 0.078
White race 96.6 96.4 0.771
Age, y
<70 52.9 58.5 <0.001
70 to 79 27.8 29.4
≥80 19.3 12.1
Smoking (prior or current) 81.7 88.6 <0.001
COPD 25.8 28.8 0.063
Hypertension 85.7 88.0 0.072
Coronary artery disease 35.6 37.6 0.236
Prior CABG or coronary
intervention
32.0 34.5 0.143
Congestive heart failure 16.5 15.5 0.466
Diabetes
No diabetes 48.5 50.3 0.581
Non–insulin-dependent
diabetes
25.8 24.4
Insulin-dependent
diabetes
25.7 25.3
Creatinine ≥1.8 9.1 7.2 0.076
Dialysis 8.2 5.6 0.004
Living nursing home
preoperatively
4.4 3.2 0.085
Transferred from hospital/
rehabilitation unit
7.6 7.6 0.973
Independently ambulatory
preoperatively
78.3 78.8 0.755
BMI, kg/m2
<20 9.3 10.7 0.125
20 to 30 62.4 61.6
30 to 40 24.6 25.3
≥40 3.7 2.3
Cardiac stress test
Not done 61.7 61.6 0.803
Normal 25.6 25.0
Abnormal 12.6 13.4
Continued
Table 1. Continued
Characteristic
Unweighted Data
Primary
LEB, %
Secondary
LEB, % P Value*
Preoperative medication regimen
Preoperative b-blockers 77.4 80.1 0.076
Preoperative aspirin 72.2 76.1 0.014
Preoperative
clopidogrel
8.3 19.3 <0.001
Preoperative statin use 63.3 70.8 <0.001
Surgical history
CEA 9.2 12.7 0.001
Aneurysm repair 2.8 6.2 <0.001
Ipsilateral major
amputation
0.0 0.4 0.025
Ipsilateral minor
amputation
5.8 7.8 0.023
Indication
Claudication 29.5 30.1 0.705
Critical limb ischemia 70.6 69.9
Operative details
Urgency
Elective 81.4 79.0 0.023
Urgent 18.2 19.8
Emergent 0.5 1.2
Graft origin—common
femoral artery
66.5 73.1 <0.001
Graft recipient
Above knee 28.3 29.0 <0.001
BK popliteal 31.5 35.8
Tibial 28.2 29.6
Pedal 12.0 5.7
Graft type
Prosthetic 27.3 35.6 <0.001
Any graft vein type 75.0 66.8 <0.001
No. of vein segments
0 26.1 33.4 <0.001
1 69.0 59.1
2 4.6 6.7
≥3 0.3 0.8
Concomitant proximal
procedures (ipsilateral)
PVI 10.8 9.3 0.297
Endarterectomy 49.6 43.1 0.007
Continued
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3.9%, P=0.822) (Table 4). Secondary LEB patients were
slightly more likely than were primary LEB patients to require
a major amputation (below-knee or above-knee) during the
index hospitalization (0.5% versus 0.1%, P=0.031).
After adjustment for intergroup differences with inverse
propensity weighting, there were no signiﬁcant differences in
overall rates of in-hospital mortality, myocardial infarction, or
ipsilateral major amputation (Table 4). However, on weighted
analysis, patients undergoing secondary LEB were more
likely to return to the operating room for graft thrombosis or
have graft occlusion at discharge than was the primary LEB
cohort (Table 4). Subgroup analyses stratiﬁed by symptom
type (claudication versus CLI) demonstrated similar results in
both the crude and inverse propensity-weighted cohorts
(Table 5).
Outcomes at 1-Year Follow-up in Primary Versus
Secondary LEB, by Indication and Procedure Type
Outcomes at 1 year differed signiﬁcantly between primary
and secondary LEB patients. In crude analyses of all patients
at 1 year after LEB, RAO-free survival and MALE-free survival
were signiﬁcantly inferior compared with primary LEB patients
(Figure 3, Table 5). Individual components of these summary
outcomes, such as survival and amputation, are shown in
Table 6. Following inverse propensity weighting, secondary
LEB was signiﬁcantly associated with inferior RAO-free
survival (hazard ratio=1.22, 95% CI 1.09 to 1.37, P<0.001)
and inferior MALE-free survival (hazard ratio=1.23, 95% CI
1.10 to 1.38, P<0.001) (Figure 4).
Subgroup analyses stratiﬁed by indication (claudication
versus CLI) demonstrated similar results in patients with CLI
but not claudicants (Table 5). For patients with CLI, MALE-free
survival at 1 year was inferior among secondary LEB patients
Table 1. Continued
Characteristic
Unweighted Data
Primary
LEB, %
Secondary
LEB, % P Value*
Anesthesia type
Spinal 13.8 11.0 0.006
Epidural 6.7 5.0
General anesthesia 79.4 84.0
Right side (origin) 51.4 53.4 0.261
Adjuncts
No vein cuff 98.2 96.6 0.003
Vein cuff 1.8 3.5
No sequential graft 97.9 97.2 0.234
Sequential graft 2.1 2.8
Discharge medications
Aspirin 80.7 82.9 0.123
Clopidogrel 16.8 25.9 <0.001
Warfarin 21.4 27.7 <0.001
Statin 74.0 79.5 0.002
b-Blocker 76.4 78.2 0.284
BK indicates below knee; BMI, body mass index; CABG, coronary artery bypass graft
surgery; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease;
LEB, lower extremity bypass; PVI, peripheral endovascular intervention.
*P value from v2 test (testing differences between patients without prior PVI or bypass
and those with either).
Table 2. Multivariate Analysis of Patient Demographics and
Operative Details, by Secondary LEB
Variable Odds Ratio 95% CI P Value
Male sex 0.78 0.66 to 0.92 0.003
Age, y
<70 Reference
70 to 79 0.93 0.78 to 1.11 0.445
≥80 0.58 0.46 to 0.74 <0.001
BMI, kg/m2
<20 Reference
20 to 30 0.78 0.60 to 1.01 0.059
30 to 40 0.75 0.56 to 0.99 0.043
≥40 0.39 0.23 to 0.66 <0.001
Smoking (prior
or current)
1.53 1.21 to 1.94 <0.001
Previous arterial
aneurysm repair
2.72 1.88 to 3.93 <0.001
Preoperative
clopidogrel
2.57 2.06 to 3.21 <0.001
Preoperative statin
use
1.31 1.11 to 1.55 0.001
Prior ipsilateral
minor amputation
1.69 1.24 to 2.32 0.001
Graft recipient
Above knee Reference
BK popliteal 1.42 1.15 to 1.74 0.001
Tibial 1.39 1.11 to 1.74 0.005
Pedal 0.64 0.46 to 0.91 0.013
Any graft vein type 0.52 0.32 to 0.86 0.010
No. of vein segments
0 Reference
1 1.13 0.69 to 1.83 0.637
2 2.18 1.22 to 3.87 0.008
≥3 4.18 1.21 to 14.48 0.024
AUC=0.67. AUC indicates area under the curve; BK, below knee; BMI, body mass index;
LEB, lower extremity bypass.
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Table 3. Selected Demographics and Operative Details of Patients (N=3504) Who Underwent Infrainguinal LEB in the Vascular
Study Group of New England From 2003 to 2011, With Univariate Analysis by Primary Versus Secondary LEB, With Inverse
Propensity Weighting
Characteristic
Unweighted Data Inverse Propensity-Weighted Analysis
Primary LEB, % Secondary LEB, % P Value* Primary LEB, % Secondary LEB, % P Value†
No. of patients 2350 1154 2350 1154
Demographics
Male sex 69.6 66.6 0.078 68.1 68.4 0.874
White race 96.6 96.4 0.771 96.6 96.2 0.569
Age, y
<70 52.9 58.5 <0.001 55.0 55.0 0.995
70 to 79 27.8 29.4 28.2 28.1
≥80 19.3 12.1 16.8 16.9
Smoking (prior or current) 81.7 88.6 <0.001 83.9 83.2 0.592
COPD 25.8 28.8 0.063 25.9 26.5 0.721
Hypertension 85.7 88.0 0.072 85.5 88.0 0.051
Coronary artery disease 35.6 37.6 0.236 36.3 35.3 0.599
Prior CABG or coronary intervention 32.0 34.5 0.143 33.4 33.1 0.842
Congestive heart failure 16.5 15.5 0.466 16.1 15.8 0.804
Diabetes
No diabetes 48.5 50.3 0.581 48.3 50.2 0.400
Non–insulin-dependent diabetes 25.8 24.4 25.7 26.0
Insulin-dependent diabetes 25.7 25.3 26.0 23.9
Creatinine ≥1.8% 9.1 7.2 0.076 8.7 7.0 0.092
Dialysis 8.2 5.6 0.004 7.9 6.2 0.075
Preoperative medication regimen
Preoperative b-blockers 77.4 80.1 0.076 77.8 79.9 0.167
Preoperative aspirin 72.2 76.1 0.014 72.7 73.8 0.509
Preoperative clopidogrel 8.3 19.3 <0.001 12.1 11.9 0.892
Preoperative statin use 63.3 70.8 <0.001 66.5 66.7 0.914
Surgical history
CEA 9.2 12.7 0.001 9.9 11.4 0.203
Aneurysm repair 2.8 6.2 <0.001 3.7 3.8 0.948
Ipsilateral major amputation 0.0 0.4 0.025 0.1 0.3 0.056
Ipsilateral minor amputation 5.8 7.8 0.023 6.3 6.1 0.896
Indication
Claudication 29.5 30.1 0.705 30.3 29.4 0.594
Critical limb ischemia 70.6 69.9 69.7 70.6
Operative details
Urgency
Elective 81.4 79.0 0.023 82.4 80.6 0.137
Urgent 18.2 19.8 17.2 18.6
Emergent 0.5 1.2 0.4 0.9
Graft origin—common femoral artery 66.5 73.1 <0.001 67.9 71.8 0.021
Continued
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(55.3% versus 63.1%, P=0.002), as was RAO-free survival
(53.0% versus 60.0%, P=0.003). Finally, to determine whether
the nature of the prior revascularization procedure (PVI, LEB, or
both) had a differential effect on the outcomes of secondary
LEB, we stratiﬁed outcomes based on prior intervention type.
We found that, regardless of the nature of the prior interven-
tion (endovascular or surgical), all secondary LEB patients had
inferior RAO-free survival (P=0.005) and MALE-free survival
(P=0.004) outcomes (Figure 5). To further clarify the impact of
prior PVI on subsequent LEBs, we compared primary LEBs with
only those secondary LEBs performed after PVI and found that
differences in RAO-free survival (P=0.005) and MALE-free
survival (P=0.005) persisted.
Discussion
With the continuing evolution of endovascular techniques for
the treatment of PAD, several studies have demonstrated
dramatic increases in the volume of interventions being
performed during the past decade, suggesting a major shift
in practice patterns toward a more aggressive use of
revascularization.1–3 Our data suggest that, currently, nearly
half of the patients undergoing surgical lower extremity
revascularization in New England represent a failure of a
prior revascularization attempt in that limb, a relative
increase of 72% over the study interval. In both crude and
weighted analyses, these secondary bypass operations are
associated with signiﬁcantly worse mid-term outcomes
compared with patients undergoing primary bypass, even
when adjusting for differences in patient characteristics.
Furthermore, primary bypass outcomes were superior to
secondary bypass outcomes, regardless of whether the prior
failed intervention was endovascular or surgical in nature.
Thus, both the incidence and the impact of treatment failure
on the treatment of PAD appear to be increasing dramat-
ically in recent years, with treatment failure contributing
Table 3. Continued
Characteristic
Unweighted Data Inverse Propensity-Weighted Analysis
Primary LEB, % Secondary LEB, % P Value* Primary LEB, % Secondary LEB, % P Value†
Graft recipient
Above knee 28.3 29.0 <0.001 29.0 29.5 0.991
BK popliteal 31.5 35.8 33.2 33.0
Tibial 28.2 29.6 28.0 27.6
Pedal 12.0 5.7 9.9 9.9
Graft type
Prosthetic 27.3 35.6 <0.001 29.8 30.2 0.791
Any graft vein type 75.0 66.8 <0.001 72.5 72.4 0.915
No. of vein segments
0 26.1 33.4 <0.001 28.3 28.4 0.984
1 69.0 59.1 66.0 65.8
2 4.6 6.7 5.4 5.4
≥3 0.3 0.8 0.3 0.4
Concomitant proximal procedures (ipsilateral)
PVI 10.8 9.3 0.297 11.0 9.1 0.203
Endarterectomy 49.6 43.1 0.007 49.4 44.4 0.038
Discharge medications
ASA 80.7 82.9 0.123 81.1 82.1 0.492
Clopidogrel 16.8 25.9 <0.001 19.1 21.5 0.107
Coumadin 21.4 27.7 <0.001 21.3 27.0 <0.001
Statin 74.0 79.5 0.002 76.1 77.8 0.328
b-Blocker 76.4 78.2 0.284 76.9 77.7 0.645
ASA indicates aspirin; BK, below knee; CABG, coronary artery bypass graft surgery; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease; LEB, lower extremity
bypass; OR, operating room; PVI, peripheral endovascular intervention.
*P value from v2 test (testing differences between weighted groups).
†P value from v2 test (testing differences between propensity-weighted groups).
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signiﬁcantly to the overall burden of PAD on patients and
the health care system.
In recent years, many have advocated an “endovascular
ﬁrst” strategy when treating patients with severe PAD.17–19
This shift in approach has occurred concomitantly with the
continued evolution and proliferation of catheter-based tech-
nologies and their diffusion across multiple disciplines and
venues of care. Among the reasons cited for more aggressive
use of endovascular revascularization, many argue that a
failed primary endovascular intervention causes little harm, as
long as the target for bypass surgery remains available.18
However, our data indicate that LEBs performed in the setting
of failed prior interventions are substantially more likely to fail
within 1 year, in comparison to primary operations. This was
true regardless of whether the prior intervention was endo-
vascular (PVI) or surgical (LEB) in nature. Moreover, the
survival curves suggest that the degree of inferiority for
secondary LEB continues to increase with time and would
likely be substantially greater with additional years of
observation.
Although these data describe the effects of evolving
treatment paradigms for PAD on patients presenting for
surgical bypass, they do not, in any way, address the question
of which primary interventions are appropriate and which are
Table 4. In-hospital Outcomes and Discharge Characteristics of Patients Who Underwent Infrainguinal LEB, With Univariate
Analysis by Primary Versus Secondary LEB and Inverse Propensity Weighting
Outcome/Discharge Characteristic
Unweighted Data Inverse Propensity-Weighted Analysis
Primary LEB, % Secondary LEB, % P Value* Primary LEB, % Secondary LEB, % P Value†
No. of patients 2350 1154 2350 1154
Postoperative complications
Return to OR
Return to OR for bleeding 1.6 1.3 0.478 1.6 1.0 0.192
Return to OR for infection 0.9 0.9 0.975 1.0 0.6 0.316
Return to OR for thrombosis 2.2 3.3 0.061 2.3 3.6 0.036
Graft occlusion at discharge 1.3 2.0 0.126 1.1 2.0 0.026
Postoperative length of stay, d‡ 4 (0 to 89) 4 (0 to 154) 0.384 4 (0 to 89) 4 (0 to 154) 0.199
In-hospital mortality 1.5 1.6 0.795 1.3 1.3 0.994
In-hospital MI 3.9 4.1 0.822 3.9 3.7 0.738
In-hospital ipsilateral amputation 0.1 0.5 0.031 0.2 0.4 0.122
LEB indicates lower extremity bypass; MI, myocardial infarction; OR, operating room.
*P value from v2 test (testing differences between unweighted groups).
†P value from v2 test (testing differences between propensity-weighted groups).
‡Median (range), P value from Wilcoxon rank sum test.
Figure 3. Crude (unweighted) analysis of RAO-free survival and MALE-free survival in primary versus secondary LEB. LEB indicates lower
extremity bypass; MALE, major adverse limb event; PVI, peripheral endovascular intervention; RAO, reintervention or amputation.
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not. Obviously, not all patients who undergo an initial
endovascular intervention will ultimately require surgical
bypass, and we readily agree that for many patients,
endovascular intervention is a reasonable, safe, and effective
initial option for treatment in PAD. In future work, we plan to
use the Vascular Quality Initiative, a recently formed national
quality improvement collaborative derived from regional
efforts in New England, to examine the need for surgical
revascularization among all patients undergoing an initial
endovascular intervention, as well as the outcomes beginning
with the ﬁrst PVI or bypass.
Our study was not designed to establish whether primary
bypass is a superior strategy to primary endovascular
approach with surgical “backup” for failures. Further evidence
from randomized trials will be necessary to address this
question.9 However, given our ﬁndings, we believe physicians
who care for patients with vascular disease should consider
the signiﬁcant inﬂuence of treatment failure on future events.
Downstream effects may not become evident for years;
therefore, outcomes reports with limited follow-up may
grossly underestimate the impact of treatment failures in
PAD. In this regard, the 1-year outcomes reported here are
also a notable limitation, though the trends suggest that the
strength of these ﬁndings would only increase with longer
observation times.
Importantly, ﬁndings from our observational dataset reﬂect
data from existing randomized trials.9 Patients surviving ≥2
years in the Bypass versus Angioplasty in Severe Ischemia of
the Limb trial (BASIL) (70% of the cohort) appeared better
served by an initial LEB, and LEB procedures that were
Figure 4. Inverse-propensity weighted analysis of RAO-free survival and MALE-free survival in primary versus secondary LEB. HR indicates
hazard ratio; LEB, lower extremity bypass; MALE, major adverse limb event; PVI, peripheral endovascular intervention; RAO, reintervention or
amputation.
Figure 5. Subgroup analysis of RAO-free survival and MALE-free survival, stratiﬁed by prior intervention type. MALE indicates major adverse
limb event; PVI, peripheral endovascular intervention; RAO, reintervention or amputation.
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performed after an initial failed PVI had notably inferior
outcomes compared with bypass performed as the initial
strategy in BASIL. While a major criticism of BASIL has been
whether the protocol-mandated use of balloon angioplasty
alone represents current best endovascular practice, our
contemporary study suggests broadly similar implications in
the present era of PVI.
Are the regional results reported in our dataset broadly
generalizable? We believe the answer is yes. Our study is
based on risk-adjusted, clinically detailed data from real-world
practice, and we used inverse propensity weighting to account
for differences in patient characteristics as well as surgical
variables such as type of conduit used and distal target. And,
given that our study cohort is composed of peripheral
vascular operations, many, but not all, of the contributors to
our dataset are vascular surgeons. In fact, of those physicians
who contribute to the VSGNE and report board certiﬁcation,
>40% are interventional cardiologists, radiologists, or proce-
dure-based specialists other than vascular surgeons. Spe-
cialty issues aside, the optimal manner by which to assess the
extended impact of initial treatment selections in patients
with advanced PAD would be a randomized trial, comparing
the clinical and functional outcomes for differing initial
treatment strategies with long-term follow-up including sec-
ondary interventions. However, given current cost constraints,
no such trials are on the immediate horizon.
How, then, should we proceed? Disease-based registries,
used in cooperation across a variety of provider specialties,
may provide a practical method to gain insight into this
complex problem. Using detailed risk adjustment algorithms,
patient-level risk for adverse outcomes can be assessed for a
variety of treatment strategies—conservative care, endovas-
cular ﬁrst, primary LEB, and secondary interventions (both PVI
and LEB). While a disease-based registry would share several
of the limitations inherent to our procedure-based registry, it
would add the beneﬁt of insight from other treatment
strategies to detect marginal differences in outcomes across
treatment types. Given that procedure-based registries are
becoming more common in the vascular community, con-
struction of disease-based registries, which include pheno-
typic information as it becomes widely available, would be a
straightforward path to follow.
These ﬁndings build on previous work by our group,5,8 in
which we examined the adverse effect of a prior failed
endovascular intervention on outcomes in subsequent lower
extremity bypass and found a rising proportion of LEBs being
performed for claudication in recent years. The present
analysis adds additional insights to this work. First, we
demonstrate that the overall incidence of secondary LEB has
dramatically increased during the past decade. In patients
with claudication, this provides evidence, albeit indirect, of a
“treatment trap.” Patients, who may have foregone open
surgery for claudication initially but chose to undergo PVI, are
now presenting for bypass surgery in increasing numbers
following failure of their PVI.1,5 Although it is generally
understood that repeat procedures will have inferior out-
comes compared with an index procedure, this study also
serves to delineate the real-world extent of this effect. As a
result, clinicians can use these results to counsel patients
regarding realistic expectations of outcomes following a
secondary LEB, thereby better informing discussions of risks
and beneﬁts of intervention. Most important, the current data
Table 6. Outcomes at 1-Year Follow-up in All Patients, With Univariate Analysis by Primary Versus Secondary LEB and Inverse
Propensity Weighting
Variable
Unweighted Data Inverse Propensity-Weighted Analysis
Primary LEB
(n=2350)
Secondary LEB
(n=1154) P Value*
Primary LEB
(n=2350)
Secondary LEB
(n=1154) P Value*
Overall survival 86.6% 88.2% 0.183 87.4% 86.8% 0.667
Amputation-free survival 77.0% 75.6% 0.459 78.0% 75.5% 0.198
RAO-free survival 64.1% 58.9% 0.017 64.7% 58.3% 0.003
Overall survival 86.6% 88.2% 0.183 87.4% 86.8% 0.667
Freedom from amputation 91.5% 88.0% 0.028 91.7% 89.9% 0.239
Freedom from any reintervention 73.5% 66.1% 0.001 73.6% 66.3% 0.002
MALE-free survival 67.5% 61.6% 0.007 67.9% 61.0% 0.002
Overall survival 86.6% 88.2% 0.183 87.4% 86.8% 0.667
Freedom from amputation 91.5% 88.0% 0.028 91.7% 89.9% 0.239
Freedom from major reintervention† 78.2% 69.9% <0.001 78.0% 70.3% <0.001
LEB indicates lower extremity bypass; MALE, freedom from death, amputation, or major reintervention; RAO, freedom from death, amputation, or any reintervention.
*P value from asymptotically v2 test with 1 df at 1 year for unweighted and weighted outcomes.
†Major reintervention, new bypass graft, a jump/interposition graft placed during a revision, or thrombectomy/thrombolysis.
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show that the mid-term outcomes of LEBs are inferior in the
setting of prior treatment failure and that the deleterious
effects of restenosis appear to transcend the nature of the
initial intervention (surgical or endovascular).
Our study has important limitations. First, while we
examined traditional outcomes such as mortality and ampu-
tation-free survival,9,12,20,21 we did not directly examine
patient-centered outcomes, such as symptom recurrence,
quality-adjusted life years, or pain-free walking distance.
Second, our study lacks data on genetic biomarkers, deﬁned
hypercoagulable states, and other phenotypic data associated
with treatment failure,22–24 and, thus, the impact of these
variables is impossible to assess for primary or secondary
bypass. Furthermore, unlike randomized controlled trials, the
technique of inverse propensity weighting can only account for
measured variables, and it is therefore possible that the
weighted cohorts differ from each other by an unmeasured
factor that is biasing the results of the model. Third, our dataset
does not contain cost-related data. There is an unmet need in
understanding how this apparent “epidemic of restenosis” in
PAD ﬁts into the national discussion around cost-effectiveness
and cost saving, particularly because the long-term implica-
tions (and costs) of an “endovascular ﬁrst” strategy are not well
understood. Additionally, given the demographics of the
hospitals in our region, our dataset contains few nonwhite
patients, limiting our generalizability in high-risk subgroups
such as African American patients.16 Our study also underes-
timates the true overall impact of restenosis on surgical
practice, because we only considered 1 limb per subject and
only the ﬁrst LEB that was recorded in the database. Fourth,
data within our registry are self-reported, and while audits of
our prior work have yet to reveal systematic underreporting of
adverse events, this potential exists.5,25 Finally, given the
observational nature of our dataset, we are obviously unable to
discern if those patients treated with secondary LEB following a
failed PVI would have achieved better outcomes if they were
treated initially with LEB. Although we used inverse propensity
weighting to account for differences between groups, con-
founding by indication and anatomic distributions of disease
undoubtedly represents a signiﬁcant limitation to the infer-
ences allowable by our ﬁndings.
In conclusion, the rate of secondary bypass operations for
infrainguinal PAD has increased dramatically in recent years,
as patients with both claudication and CLI are more likely to
receive LEB following a failed prior PVI or LEB in that limb. Our
data indicate that nearly 1 of 2 LEBs currently performed is in
the setting of a prior failed infrainguinal revascularization in
the same limb. Patients undergoing secondary LEB have
poorer outcomes than patients who undergo LEB as a primary
procedure, regardless of the nature of the ﬁrst intervention.
Efforts to reduce this rising burden of restenosis in the
periphery should focus on the development of evidence-based
algorithms to guide patient selection for initial treatment,
developing new technologies to improve the durability of both
endovascular and surgical interventions, and closer examina-
tion of the impact of failed revascularizations on functional
and quality of life outcomes to improve both the quality and
value of PAD care.
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